Incyte Corp. Stock Advances 9.3%, Outperforms Peers

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Incyte Corp. rallied 9.3% to $129.93 on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.2% to 7,428.78 and the Dow Jones Industrial Average rising 1.0% to 52,747.32.

This was the stock's fourth consecutive day of gains.

Incyte Corp. hit a new 52-week high, surpassing its previous peak of $120.71, which the company achieved on July 27th.

The stock outperformed some of its peers, as Alnylam Pharmaceuticals Inc. rose 3.6% to $288.41, Bio-Techne Corp. rose 0.6% to $72.07, and BioMarin Pharmaceutical Inc. rose 2.99% to $62.07.

Trading volume totaled 5.9 million, compared to the 50-day average of 1.8 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

July 28, 2026 16:33 ET (20:33 GMT)